#ESMO26 Abstracts Are Out! In our meta-analysis with the @OncBrothers (Rohit and Rahul), we compared first-line BRAF/MEK inhibitors with ICI-based regimens in BRAF V600E-mutant aNSCLC. Among 589 patients, BRAF/MEKis achieved higher response rates (61% vs 48%), with no differences in PFS or OS👇